Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Rating) Director Thomas E. Timbie sold 4,904 shares of the stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $19.04, for a total transaction of $93,372.16. Following the completion of the transaction, the director now directly owns 1,499,069 shares of the company’s stock, valued at approximately $28,542,273.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Treace Medical Concepts Price Performance
Treace Medical Concepts stock traded down $0.01 during trading hours on Friday, hitting $19.57. 259,024 shares of the stock were exchanged, compared to its average volume of 205,917. The company has a debt-to-equity ratio of 0.34, a quick ratio of 7.56 and a current ratio of 8.28. The stock has a market capitalization of $1.08 billion, a P/E ratio of -39.14 and a beta of 0.06. Treace Medical Concepts, Inc. has a 12 month low of $12.48 and a 12 month high of $31.02. The business’s 50-day moving average is $15.95 and its two-hundred day moving average is $17.76.
Treace Medical Concepts (NASDAQ:TMCI – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The firm had revenue of $29.05 million for the quarter, compared to analysts’ expectations of $26.18 million. Treace Medical Concepts had a negative net margin of 25.92% and a negative return on equity of 28.57%. During the same period in the prior year, the firm earned ($0.07) earnings per share. Equities research analysts expect that Treace Medical Concepts, Inc. will post -0.64 EPS for the current fiscal year.
Institutional Trading of Treace Medical Concepts
Wall Street Analysts Forecast Growth
TMCI has been the subject of several recent research reports. Morgan Stanley dropped their price target on shares of Treace Medical Concepts from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. BTIG Research initiated coverage on shares of Treace Medical Concepts in a research report on Thursday, May 12th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Stifel Nicolaus dropped their price target on shares of Treace Medical Concepts from $32.00 to $21.00 in a research report on Monday, July 18th.
Treace Medical Concepts Company Profile
Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.
- Get a free copy of the StockNews.com research report on Treace Medical Concepts (TMCI)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.